LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Researchers Seek Disease Biomarkers Hidden in the Long Noncoding RNA Segment of the Genome

By LabMedica International staff writers
Posted on 01 Feb 2015
Print article
Researchers have analyzed the large segment of DNA in the human genome that underlies the species of nucleic acids called long noncoding RNAs (lncRNA), a genre that functions as important regulators of tissue physiology and disease processes including cancer.

To delineate genome-wide lncRNA expression, investigators at the University of Michigan (Ann Arbor, USA) evaluated 7,256 RNA sequencing (RNA-seq) libraries from tumors, normal tissues, and cell lines comprising over 43 terabytes of nucleotide sequence from 25 independent studies.

Evaluation of this data set, as described in the January 19, 2015, online edition of the journal Nature Genetics, yielded a consensus human transcriptome of 91,013 expressed genes. Over 68% (58,648) of genes were classified as coding for lncRNAs, of which 79% were previously unannotated. About 1% (597) of the lncRNAs harbored ultraconserved elements, and 7% (3,900) overlapped disease-associated SNPs (single nucleotide polymorphisms). The complete dataset, named the MiTranscriptome compendium, has been made available to the scientific community online (Please see Related Links below).

To prioritize lineage-specific, disease-associated lncRNA expression, the investigators employed nonparametric differential expression testing and nominated 7,942 lineage- or cancer-associated lncRNA genes. One lncRNA, SChLAP1, was identified as a potential biomarker for aggressive prostate cancer. This RNA was more highly expressed in metastatic prostate cancer than in early stage disease and was found primarily in prostate cancer cells, not in other cancers or normal cells.

"Some long non-coding RNAs tend to be exquisitely specific for cancer, while protein-coding genes are often not. That is what makes lncRNAs a very promising target for developing biomarkers," said senior author Dr. Arul M. Chinnaiyan, professor of pathology at the University of Michigan. "We hope that researchers will investigate the MiTransciptome compendium and begin to nominate lncRNAs for further study and development. It is likely that only a subset of these has true function but as a previously untapped area, it holds great promise. We know about protein-coding genes, but that represents only 1%–2% of the genome. Much less is known about the biology of the noncoding genome in terms of how it might function in a human disease like cancer."

Related Links:

University of Michigan
MiTranscriptome


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more